Liberty Caps in Homeopathy: What the References Say and What They Don’t

Curiosity meets evidence. AI-generated editorial illustration for GrowTheFunguy; a visual metaphor, not a species-identification image.

A name in a remedy index can look like proof.

It is only a starting point.

The liberty cap, Psilocybe semilanceata, does appear in homeopathic literature. There are books, a toxicology article, and at least one published case history that discuss it. Those references make the subject worth examining. They do not establish that a homeopathic preparation treats paranoia, intrusive thoughts, depression, or any other condition.

At GrowTheFunguy, we work with fungi every day. That makes careful language more important, not less. A mushroom’s name, its chemistry, a traditional story, and a health claim are four different things. They deserve four different kinds of evidence.

First, get the mushroom right

“Magic mushroom” is a broad common name, not a species. Psilocybe semilanceata is the liberty cap. Psilocybe cubensis is another species. They are not interchangeable names, even though both can contain psilocybin.

This distinction matters when reading the homeopathic record. A source about P. semilanceata cannot automatically be used as evidence about P. cubensis, or vice versa. Start with the Latin name. Then check what the source actually studied.

Liberty cap, catalogued as Psilocybe semilanceata. Photograph: Dr. Hans-Günter Wagner, via Wikimedia Commons, CC BY-SA 2.0. Used without visual alterations. Photographs here are for context, not a foraging or identification guide.

What the homeopathic references contain

Frans Vermeulen includes Psilocybe semilanceata in Kingdom Fungi: Spectrum Materia Medica, Volume 2. His summary associates the remedy with opposing emotional states, altered time and space, laughter, coldness, and numbness. This is a materia medica synthesis: a practitioner-oriented description drawing together themes and reports. It is not a modern clinical trial.

In 2002, M. S. Bonnet, P. W. Basson, and D. L. Bonnet published “The toxicology of Psilocybe semilanceata, the liberty cap” in Homeopathic Links. Its appearance in a homeopathy journal makes it relevant to the history of the remedy. The title also tells us what kind of paper it is: toxicology, not a controlled test showing that a homeopathic product is effective.

The North American Society of Homeopaths’ 2018 journal contents list Givon Zirkind’s “Psilocybe semilanceata (Liberty Cap Mushroom): A Case History.” A case history can show how a practitioner reasoned through one person’s situation. By itself, it cannot tell us whether improvement was caused by the remedy, what would have happened without it, or whether the result applies to other people.

There is another useful check. The homeopathic database provings.info says that it knows of no published proving for P. semilanceata. That is a database’s account of the record, not proof that no proving has ever existed. Still, it is a reason to be precise when calling a description a “proving.”

A repertory detail worth checking

The article that prompted this search highlights the rubric “under superhuman control.” In the public Kent repertory view on OpenHomeopath, that rubric lists Agar., Anac., Lach., Naja, and Thuj. It does not list Psil-s. The public Psil-s remedy page also reports no corresponding symptoms in its Kent repertory view.

Different repertories and editions can differ. So this does not prove that no homeopathic source ever connects the idea with the remedy. It does mean the claim needs a specific citation: the repertory, edition, rubric, and remedy entry. A symptom should not be attributed to a remedy merely because it appears nearby in an article.

Psilocybin research and the questions ahead

Researchers have studied psilocybin administered at pharmacological doses in controlled settings, often alongside psychological support. For example, a Johns Hopkins randomized clinical trial studied psilocybin-assisted therapy for major depressive disorder. That research concerns the active drug, participant screening, clinical monitoring, and a defined therapeutic protocol.

The homeopathic literature raises questions worth investigating. A useful next step is to document the exact preparation, the published observations, and the research needed to evaluate the proposed use.

We approach this work with an open mind and a commitment to careful investigation. A research programme should define its preparation, methods, and outcomes clearly, and report its findings transparently.

A field photograph catalogued as Psilocybe semilanceata. Photograph: jakelee, via Wikimedia Commons, CC0 1.0. Used without visual alterations; credit retained as a courtesy.

A homeopathic pathway toward regulated access in India

A proposal for discussion, researched on 4 November 2026. It is not a statement that a particular product, institution, or activity has permission.

At GrowTheFunguy, we are exploring the homeopathic route toward legal recognition and regulated access in India. The existing materia medica, toxicology references, and case literature provide a starting point for an institutional proposal. AYUSH research institutions and drug-standardisation expertise could help develop that proposal.

Psilocybin and psilocin appear in the Schedule to the NDPS Act. Section 8(c) allows medical or scientific purposes only within the Act, rules, orders, and applicable permissions. Calling something a research project does not supply those permissions. [8]

There is an important distinction between that Act's Schedule and the separate Schedule I of the NDPS Rules. The Schedule I published by CBN in its 2025 materials does not list psilocybin or psilocin. Their absence from that particular list does not remove NDPS control. The Department of Revenue explains that different scheduling categories affect the manufacturing route; current amendments and the proposed activity still need to be checked. [9–10]

AYUSH also contains different systems with different rules. A reference in a homeopathic book does not establish an Ayurvedic formulation. For a proposed new homeopathic medicine, CDSCO's circular of 4 May 2026 sets out an NOC process covering scientific justification, quality, safety, and clinical information. Whether this exact species and preparation fit an existing recognised standard or require new-medicine approval needs a written regulatory answer. [11]

For this homeopathic pathway, we propose three steps:

1. Build the homeopathic dossier. Confirm the exact species and preparation, assemble the materia medica and clinical references, and establish its status in the applicable recognised pharmacopoeias. Document the evidence already available and the questions that remain.
2. Establish the regulatory route. Seek written classification from CDSCO's Ayush Division and the relevant state licensing authority. Determine whether new-homeopathic-medicine approval is required, and identify the NDPS permissions applicable to the proposed source material and activities.
3. Develop an institutional research programme. Work with qualified researchers on identity, quality, safety, and the proposed therapeutic use. Obtain the applicable approvals before the work begins, then use the resulting evidence to support an application for regulated homeopathic access.

Our suggested sequence is practical: begin with a literature and regulatory review; seek written guidance from CDSCO, the relevant state licensing authority, and the appropriate NDPS authorities; then propose authorised laboratory work on identity, quality, and consistency. Human studies would come later, if justified, with the required permissions, ethics review, prospective registration, and clinical safeguards. Trial registration itself is not regulatory approval. [12]

A Kerala institution worth approaching for an initial academic discussion is CCRH's National Homoeopathy Research Institute in Mental Health, Kottayam. Its existence and mental-health research remit are established; its participation in this proposal is not. Pharmacopoeial questions could be put to PCIM&H, whose role concerns official quality standards. [13–14]

A 2026 viewpoint by NIMHANS-affiliated authors also discusses India's psilocybin-research opportunity. It is an argument for investigation, not a trial result or government clearance. [15]

For GrowTheFunguy, the immediate contribution could be a homeopathic evidence dossier and an institutional proposal. Any role involving controlled source material would require the applicable lawful authorisation. Our next question is practical: what evidence and permissions would India require to investigate this preparation and consider regulated homeopathic access?

Keep curiosity. Keep the categories clear.

There is a legitimate reference trail for Psilocybe semilanceata in homeopathic literature: Vermeulen’s materia medica, the Bonnet toxicology paper, and Zirkind’s case history. There is also a notable gap: the sources we found do not establish reliable clinical effectiveness, and the database we checked does not identify a published proving.

That is enough to write about the remedy’s place in homeopathic literature. It is not enough to recommend it as treatment or call it safer than the mushroom itself. Claims about paranoia, intrusive thoughts, or other mental-health symptoms need evidence that directly supports those claims—and people experiencing them deserve qualified care, not a leap from an interesting reference to a promise.

Fungi reward curiosity. Good science rewards the discipline to stop where the evidence stops.

This article is educational and is not medical advice. Do not use homeopathic products or psychoactive mushrooms as a substitute for appropriate medical care. Psilocybin-containing mushrooms can cause serious psychological and physical effects, and laws vary by location.

Sources

1. Vermeulen, Frans. Kingdom Fungi: Spectrum Materia Medica, Volume 2. Publisher’s reading excerpt. See the Psilocybe semilanceata section, listed around pp. 145–154.
2. Bonnet, M. S., Basson, P. W., & Bonnet, D. L. (2002). “The toxicology of Psilocybe semilanceata, the liberty cap.” Homeopathic Links, 15(4), 251–257. University of Bristol record.
3. Zirkind, Givon. (2018). “Psilocybe semilanceata (Liberty Cap Mushroom): A Case History.” The American Homeopath, Volume 24. Journal contents and PDF.
4. provings.info: Psilocybe semilanceata (Psil-s.).
5. OpenHomeopath: Psilocybe semilanceata materia medica record; Kent rubric: “under superhuman control”.
6. National Center for Complementary and Integrative Health. Homeopathy.
7. Griffiths, R. R., et al. (2021). “Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.” JAMA Psychiatry, 78(5), 481–489. PubMed.
8. NDPS Act, Section 8 and Schedule: India Code; CBN's consolidated Act and Rules, 2025 edition. The legal discussion is a research roadmap, not an opinion on any individual's permission to possess or supply material.
9. Central Bureau of Narcotics. Schedule I of the NDPS Rules, as published in its 2025 materials. This is distinct from both the Act's Schedule and international scheduling.
10. Department of Revenue. Manufacture of Psychotropic Substances. Read with CBN's current notifications, rather than treating a consolidated edition as an exhaustive update service.
11. CDSCO, Ayush Division. Circular and checklist for an NOC to manufacture/import a new homoeopathic medicine, 4 May 2026; official Ayush notices page. See also the Drugs Rules, Rules 2(dd), 30AA, and 85C; preparation-specific classification requires confirmation.
12. Clinical Trials Registry–India. Registration requirements and scope.
13. CCRH. National Homoeopathy Research Institute in Mental Health, Kottayam.
14. PCIM&H. Pharmacopoeial standards and their legal status: official FAQ.
15. Tom, A., Reddy, B. S. C., Sethi, M. I. S., & Math, S. B. (2026). “India's Unique Legal Framework for Psilocybin Mushroom Research: An Unprecedented Opportunity in Psychiatric Therapeutics.” Indian Journal of Psychological Medicine. Original viewpoint. DOI: 10.1177/02537176261416347.

Image credits

The two photographs are freely reusable under their individual licences, including commercial use subject to applicable terms. Wagner's image requires attribution and a licence link; adaptations must follow its share-alike terms. The jakelee image is dedicated to the public domain under CC0. The AI hero is clearly labelled as conceptual artwork. The accompanying article package includes the image files, captions, alt text, and production notes.